Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Schotsaert, Michael ^a,b,d   Ysenbaert, Tine ^a,b   Smet, Anouk ^a,b   Schepens, Bert ^a,b   Vanderschaeghe, Dieter ^a,b   Stegalkina, Svetlana ^c   Vogel, Thorsten U ^c   Callewaert, Nico ^a,b   Fiers, Walter ^a,b   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c SANOFI PASTEUR   (France)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; SIALIDASE;

ANIMAL; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CROSS REACTION; FEMALE; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MOUSE; PHYSIOLOGY; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; NEURAMINIDASE; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 84963957477     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24402     Document Type: Article

References (63)

1. Epstein, S. L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193, 49-53 (2006).
2. McMichael, A. J., Gotch, F. M., Noble, G. R. & Beare, P. A. Cytotoxic T-cell immunity to influenza. N Engl J Med 309, 13-17 (1983).
3. Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19, 1305-1312, doi: 10.1038/nm.3350 (2013).
4. Kreijtz, J. H. et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25, 612-620 (2007).
5. Schulman, J. L. & Kilbourne, E. D. Induction of Partial Specific Heterotypic Immunity in Mice by a Single Infection with Influenza a Virus. J Bacteriol 89, 170-174 (1965).
6. Weinfurter, J. T. et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. Plos Pathog 7, e1002381 (2011).
7. Kreijtz, J. H. et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27, 4983-4989, doi: 10.1016/j.vaccine.2009.05.079 (2009).
8. Bodewes, R. et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 85, 2695-2702 (2011).
9. Yap, K. L., Ada, G. L. & McKenzie, I. F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273, 238-239 (1978).
10. Seo, S. H. & Webster, R. G. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 75, 2516-2525 (2001).
11. Bodewes, R. et al. Annual vaccination against influenza virus hampers development of virus-specific CD8(+) T cell immunity in children. J Virol 85, 11995-12000 (2011).
12. Bodewes, R. et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. Plos one 4, e5538, doi: 10.1371/journal.pone.0005538 (2009).
13. Schotsaert, M. et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol 6, 276-287 (2013).
14. Bodewes, R., Kreijtz, J. H. & Rimmelzwaan, G. F. Yearly influenza vaccinations: a double-edged sword? Lancet Infect Dis 9, 784-788 (2009).
15. Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67, 2552-2558 (1993).
16. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856, doi: 10.1126/science.1205669 (2011).
17. Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102-106, doi: 10.1038/nature12202 (2013).
18. Krammer, F. & Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3, 521-530, doi: 10.1016/j.coviro.2013.07.007 (2013).
19. Steel, J. et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1, doi: 10.1128/mBio.00018-10 (2010).
20. DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med 20, 143-151, doi: 10.1038/nm.3443 (2014).
21. Schulman, J. L., Khakpour, M. & Kilbourne, E. D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2, 778-786 (1968).
22. Neirynck, S. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5, 1157-1163 (1999).
23. Wohlbold, T. J. et al. Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice. MBio 6, doi: 10.1128/mBio.02556-14 (2015).
24. Schotsaert, M., De Filette, M., Fiers, W. & Saelens, X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8, 499-508, doi: 10.1586/erv.09.6 (2009).
25. Bodewes, R. et al. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. The J Gen Virol 91, 1743-1753, doi: 10.1099/vir.0.020784-0 (2010).
26. Easterbrook, J. D. et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432, 39-44, doi: 10.1016/j.virol.2012.06.003 (2012).
27. Wan, H. et al. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87, 9290-9300, doi: 10.1128/JVI.01203-13 (2013).
28. Rockman, S. et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 87, 3053-3061, doi: 10.1128/JVI.02434-12 (2013).
29. Quan, F. S. et al. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 430, 127-135, doi: 10.1016/j.virol.2012.05.006 (2012).
30. Deroo, T., Jou, W. M. & Fiers, W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14, 561-569 (1996).
31. Compans, R. W., Dimmock, N. J. & Meier-Ewert, H. Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol 4, 528-534 (1969).
32. Palese, P. & Compans, R. W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-Ntrifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33, 159-163 (1976).
33. Sandbulte, M. R. et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci USA 108, 20748-20753, doi: 10.1073/pnas.1113801108 (2011).
34. Westgeest, K. B. et al. Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. J Gen Virol 93, 1996-2007, doi: 10.1099/vir.0.043059-0 (2012).
35. Air, G. M. Influenza neuraminidase. Influenza Other Respir Viruses 6, 245-256, doi: 10.1111/j.1750-2659.2011.00304.x (2012).
36. Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207, 974-981, doi: 10.1093/infdis/jis935 (2013).
37. Bosch, B. J. et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J Virol 84, 10366-10374, doi: 10.1128/JVI.01035-10 (2010).
38. Laroy, W., Contreras, R. & Callewaert, N. Glycome mapping on DNA sequencing equipment. Nat Protoc 1, 397-405, doi: 10.1038/ nprot.2006.60 (2006).
39. Dowdle, W. R., Downie, J. C. & Laver, W. G. Inhibition of virus release by antibodies to surface antigens of influenza viruses. J Virol 13, 269-275 (1974).
40. Kilbourne, E. D., Laver, W. G., Schulman, J. L. & Webster, R. G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2, 281-288 (1968).
41. Su, B. et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). Plos one 4, e8495, doi: 10.1371/journal.pone.0008495 (2009).
42. Kingstad-Bakke, B., Kamlangdee, A. & Osorio, J. E. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge. Vaccine 33, 5155-5162, doi: 10.1016/j.vaccine.2015.08.005 (2015).
43. Ibanez, L. I. et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. Plos one 8, e59081, doi: 10.1371/journal.pone.0059081 (2013).
44. El Bakkouri, K. et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J immunol 186, 1022-1031, doi: 10.4049/jimmunol.0902147 (2011).
45. Moyron-Quiroz, J. E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 10, 927-934, doi: 10.1038/nm1091 (2004).
46. GeurtsvanKessel, C. H. et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med 206, 2339-2349, doi: 10.1084/jem.20090410 (2009).
47. Laszlo, G., Hathcock, K. S., Dickler, H. B. & Hodes, R. J. Characterization of a novel cell-surface molecule expressed on subpopulations of activated T and B cells. J Immunol 150, 5252-5262 (1993).
48. Kaech, S. M. et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4, 1191-1198, doi: 10.1038/ni1009 (2003).
49. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22, 745-763, doi: 10.1146/annurev.immunol.22.012703.104702 (2004).
50. Ramos, E. L. et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 211, 1038-1044, doi: 10.1093/infdis/jiu539 (2015).
51. Kilbourne, E. D. et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13, 1799-1803 (1995).
52. Johansson, B. E., Moran, T. M. & Kilbourne, E. D. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 84, 6869-6873 (1987).
53. Chen, J. R. et al. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci USA 111, 2476-2481, doi: 10.1073/pnas.1323954111 (2014).
54. Wiley, J. A., Hogan, R. J., Woodland, D. L. & Harmsen, A. G. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J Immunol 167, 3293-3299 (2001).
55. Hillaire, M. L. et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 92, 2339-2349 (2011).
56. Johansson, B. E. & Kilbourne, E. D. Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections. J Infect Dis 162, 800-809 (1990).
57. Rangel-Moreno, J. et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 116, 3183-3194, doi: 10.1172/JCI28756 (2006).
58. Rangel-Moreno, J., Moyron-Quiroz, J. E., Hartson, L., Kusser, K. & Randall, T. D. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci USA 104, 10577-10582, doi: 10.1073/pnas.0700591104 (2007).
59. Neyt, K., Perros, F., GeurtsvanKessel, C. H., Hammad, H. & Lambrecht, B. N. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol 33, 297-305, doi: 10.1016/j.it.2012.04.006 (2012).
60. Eckert, D. M., Malashkevich, V. N. & Kim, P. S. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 284, 859-865, doi: 10.1006/jmbi.1998.2214 (1998).
61. Schmidt, P. M., Attwood, R. M., Mohr, P. G., Barrett, S. A. & McKimm-Breschkin, J. L. A generic system for the expression and purification of soluble and stable influenza neuraminidase. Plos one 6, e16284, doi: 10.1371/journal.pone.0016284 (2011).
62. Lambre, C. R., Terzidis, H., Greffard, A. & Webster, R. G. An enzyme-linked lectin assay for sialidase. Clinica chimica acta 198, 183-193 (1991).
63. REED, L. J. & MUENCH, H. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS. Am J Epidemiol 27, 493-497 (1938).